Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma

International Journal of Cancer

Volumn 127, Issue 8, 2010, Pages 1948-1957

  Suzuki, Yoshinori ^a,b   Sakai, Katsuya ^c   Ueki, Junko ^a   Xu, Qing ^b   Nakamura, Takahiro ^b   Shimada, Hideaki ^d   Nakamura, Toshikazu ^c   Matsumoto, Kunio ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

angiogenesis; HGF; invasion; malignant mesothelioma; Met

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; COLLAGEN GEL; NK 4; SCATTER FACTOR RECEPTOR; TYROSINE; UNCLASSIFIED DRUG; HGF PROTEIN, HUMAN; MESSENGER RNA; SCATTER FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MALIGNANT MESOTHELIOMA; METASTASIS; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CELL ADHESION; CELL MOTION; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; MESOTHELIOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PLEURA EFFUSION; PLEURA TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; VASCULARIZATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 77956992010     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25197     Document Type: Article

References (34)

1. Antiman KH,. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981; 8: 313-20.
2. Nakamura T, Nawa K, Ichihara A,. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122: 1450-9.
3. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S,. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3.
4. Miyazawa K, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, Nakayama H, Hirono S, Sakiyama O, Takahashi K, Gohda E, Daikuhara Y, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 1989; 163: 967-73.
5. Birchmeier C, Gherardi E,. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998; 8: 404-11.
6. Funakoshi H, Nakamura T,. Hepatocyte growth factor: from diagnosis to clinical applications. Clin Chim Acta 2003; 327: 1-23.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF,. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
8. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T,. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005; 53: 35-69.
9. Matsumoto K, Nakamura T,. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer 2006; 119: 477-83.
10. Comoglio PM, Giordano S, Trusolino L,. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev 2008; 7: 504-16.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 18 (316): 1039-43.
12. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with EGF Receptor activating mutations. Cancer Res 2008; 68: 6479-87.
13. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T,. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997; 420: 1-6.
14. Matsumoto K, Nakamura T,. Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 2005; 333: 316-27.
15. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T,. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60: 6737-43.
16. Sakai K, Nakamura T, Matsumoto K, Nakamura T,. Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by Perlecan-NK4 association. J Biol Chem 2009; 284: 22491-9.
17. Raymond WW, Cruz AC, Caughey GH,. Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists. J Biol Chem 2006; 281: 1489-94.
18. Klominek J, Baskin B, Liu Z, Hauzenberger D,. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 1998; 76: 240-9.
19. Tolnay E, Kuhnen C, Wiethege T, König JE, Voss B, Mller KM,. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998; 124: 291-6.
20. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR,. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 2000; 83: 1147-53.
21. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 352-61.
22. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, Nakamura T,. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001; 61: 7518-24.
23. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, Hida T,. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 387-94.
24. Maemondo M, Narumi K, Saijo Y, Usui K, Yahara M, Tazawa R, Hagiwara K, Matsumoto K, Nakamura T, Nukiwa T,. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF-antagonist NK4 for cancer therapy. Molecular Ther 2002; 5: 177-85.
25. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T,. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 2004; 11: 419-30.
26. Murakami J, Li TS, Ueda K,., Tanaka T, Hamano K,. Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int J Cancer 2009; 124: 1685-92.
27. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C,. Crystal structure of the HGF ?-chain in complex with the Sema domain of the Met receptor. EMBO J 2004; 23: 2325-35.
28. Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT,. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 2003; 63: 3539-45.
29. Harvey P, Warn A, Newman P, Perry LJ, Ball RY, Warn RM,. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J Pathol 1996; 180: 389-394.
30. Thirkettle I, Harvey P, Hasleton PS, Ball RY, Warn RM,. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 2000; 36: 522-8.
31. Eagles G, Warn A, Ball RY, Baillie-Johnson H, Arakaki N, Daikuhara Y, Warn RM,. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer 1996; 73: 377-81.
32. Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T, Ikeda Y,. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells in vivo; molecular targeting of angiogenic growth factor. Blood 2007; 109: 3042-9.
33. Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S,. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007; 13: 5918-25.
34. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P,. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.